Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer

PURPOSE: In 2002, pegfilgrastim was approved by the US Food and Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone receptor (HR) –negative tumors, were reported. We examined first-cycle colony-stimulating factor use (FC-CSF) before and after 2002 an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hershman, Dawn L., Wilde, Elizabeth T., Wright, Jason D., Buono, Donna L., Kalinsky, Kevin, Malin, Jennifer L., Neugut, Alfred I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3295569/
https://ncbi.nlm.nih.gov/pubmed/22312106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.7499
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados